Authors
Latest:
Dr. Tabrizian on the Rationale for Examining Cemiplimab in HCCParissa Tabrizian, MD, discusses the rationale for examining cemiplimab in hepatocellular carcinoma.
Latest:
How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBADrs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.
Latest:
Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate CancerYung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.
Latest:
Ra-223 Displays Efficacy, Safety in mCRPC With Bone MetastasesRadium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.
Latest:
Dr Goodman on the Addition of CRT to Adjuvant Chemo in Pancreatic Head AdenocarcinomasKaryn A. Goodman, MD, MS, discusses the use of chemoradiation after adjuvant chemotherapy in resected adenocarcinomas of the pancreatic head.
Latest:
Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and BispecificsExpert perspective on advancements in cancer immunotherapy, including CAR-T cells, allogeneic strategies, and the role of bispecific antibodies.
Latest:
Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory MyelomaCarolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical TrialsKatianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.
Latest:
Differentiated Thyroid Cancer: Unmet Needs and Future DirectionsExperts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.
Latest:
Tulane Doctors Extend Their Reach in 2024The Tulane Transplant Institute offers comprehensive disease management for patients with end-stage organ disease of the kidney, liver, and pancreas.
Latest:
Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPCOlivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.
Latest:
Dr. Ligresti on the Need for Screening in Pancreatic CancerRosario Ligresti, MD, discusses the need for screening in pancreatic cancer.
Latest:
Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate CancerMonica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.
Latest:
Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic MalignanciesAndrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.
Latest:
Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic AnalysisAn economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Latest:
Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCNSangeetha Venugopal, MD, MS, discusses pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN). PVEK showed promising response rates in treatment-naïve BPDCN patients in an early trial and was reasonably well-tolerated without concerning safety signals. Its FDA breakthrough therapy designation in relapsed/refractory BPDCN was based on phase 1 data suggesting good efficacy even after tagraxofusp (TAG). Early trials also support PVEK's potential in CD123+ acute myeloid leukemia, both as monotherapy and when combined with other agents like azacitidine and venetoclax.
Latest:
Dr Mehta on Radiation Oncology Innovations in Prostate CancerMinesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.
Latest:
Dr. Chu on Ongoing Efforts to Address Disparities in Lung CancerEdward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.
Latest:
Dr Aggarwal on Data for CAN-2409 Plus Valacyclovir and Continued ICIs in NSCLCCharu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.
Latest:
Case Studies with Hepatic Artery InfusionRyan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, review cases of patients with colorectal cancer and provide insights on clinical practice.
Latest:
Dr Hashmi on Real-World Teclistamab Use in Relapsed/Refractory Multiple MyelomaHamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Ravi on the Investigation of RCB Following ARPI Treatment in High-Risk Prostate CancerPraful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.
Latest:
Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast CancerTufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Final Thoughts on EHA 2024 Data for Lower-Risk MDSKey opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
Latest:
Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCLVictor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.
Latest:
Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal DiseaseKamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.
Latest:
Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal CancerResearch published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.
Latest:
Rethinking How We Approach Stage 3 Lung Cancer TreatmentAs ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.
Latest:
Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate CancerMichael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.
